(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 50.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.31%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.91%.
Kura Oncology's revenue in 2026 is $77,225,000.On average, 17 Wall Street analysts forecast KURA's revenue for 2026 to be $8,419,944,667, with the lowest KURA revenue forecast at $6,758,338,225, and the highest KURA revenue forecast at $9,888,862,408. On average, 16 Wall Street analysts forecast KURA's revenue for 2027 to be $17,374,008,891, with the lowest KURA revenue forecast at $11,818,418,234, and the highest KURA revenue forecast at $27,227,287,051.
In 2028, KURA is forecast to generate $22,700,081,150 in revenue, with the lowest revenue forecast at $14,079,797,169 and the highest revenue forecast at $39,776,071,967.